Open AccessCobalt Protoporphyrin Pretreatment Protects Human Embryonic Stem Cell‐Derived Cardiomyocytes From Hypoxia/Reoxygenation Injury In Vitro and Increases Graft Size and Vascularization In Vivo
Author(s) -
Luo Jun,
Weaver Matthew S.,
Cao Baohong,
Dennis James E.,
Van Biber Benjamin,
Laflamme Michael A.,
Allen Margaret D.
Publication year - 2014
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0189
Subject(s) - embryonic stem cell , in vivo , hypoxia (environmental) , in vitro , microbiology and biotechnology , stem cell , induced pluripotent stem cell , chemistry , biology , andrology , biochemistry , medicine , gene , oxygen , organic chemistry
These experiments demonstrate that ex vivo pretreatment of human embryonic stem cell‐derived cardiomyocytes with a single dose of cobalt protoporphyrin before intramyocardial implantation more than doubled resulting graft size and improved early graft vascularization in acutely infarcted hearts. These findings open the door for delivery of these, or other, stem cells during acute interventional therapy following myocardial infarction or ischemia.